

STEINMETZ MICHAEL
Form 4
January 08, 2010

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Clarus Lifesciences II, L.P.

(Last) (First) (Middle)

C/O CLARUS VENTURES,
LLC, 101 MAIN STREET, SUITE
1210

(Street)

CAMBRIDGE, MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ACHILLION
PHARMACEUTICALS INC
[ACHN]

3. Date of Earliest Transaction
(Month/Day/Year)
01/06/2010

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

___ Director ___X___ 10% Owner
___ Officer (give title below) ___ Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)
Common Stock	01/06/2010		S ⁽¹⁾	49,400 D	\$ 3.5027 4,624,167	I	By Fund (2)
Common Stock	01/07/2010		S ⁽¹⁾	3,600 D	\$ 3.5 4,620,567	I	By Fund (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

SEC 1474
(9-02)

number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Owned Following Reporting Transaction (Instr. 5)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Clarus Lifesciences II, L.P. C/O CLARUS VENTURES, LLC 101 MAIN STREET, SUITE 1210 CAMBRIDGE, MA 02142		X		
Clarus Ventures II GP, L.P. C/O CLARUS VENTURES, LLC 101 MAIN STREET, SUITE 1210 CAMBRIDGE, MA 02142		X		
Clarus Ventures II, LLC C/O CLARUS VENTURES, LLC 101 MAIN STREET, SUITE 1210 CAMBRIDGE, MA 02142		X		
LIPTAK ROBERT C/O CLARUS VENTURES, LLC 101 MAIN STREET, SUITE 1210 CAMBRIDGE, MA 02142		X		
Simon Nicholas C/O CLARUS VENTURES, LLC 101 MAIN STREET, SUITE 1210 CAMBRIDGE, MA 02142	X	X		
HENNER DENNIS C/O CLARUS VENTURES, LLC 101 MAIN STREET, SUITE 1210		X		

CAMBRIDGE, MA 02142

GALAKATOS NICHOLAS
 C/O CLARUS VENTURES, LLC X
 101 MAIN STREET, SUITE 1210
 CAMBRIDGE, MA 02142

Leiden Jeffrey
 C/O CLARUS VENTURES, LLC X
 101 MAIN STREET, SUITE 1210
 CAMBRIDGE, MA 02142

WHEELER KURT
 C/O CLARUS VENTURES, LLC X
 101 MAIN STREET, SUITE 1210
 CAMBRIDGE, MA 02142

STEINMETZ MICHAEL
 C/O CLARUS VENTURES, LLC X
 101 MAIN STREET, SUITE 1210
 CAMBRIDGE, MA 02142

Signatures

_____ Robert Liptak, Manager of Clarus Ventures II,
 LLC, general partner of Clarus Ventures II GP, L.P., general partner of Clarus Lifesciences II,
 L.P. 01/08/2010

__Signature of Reporting Person Date

_____ Robert Liptak, Maganer of Clarus Ventures II,
 LLC, general partner of Clarus Ventures II GP, L.P. 01/08/2010

__Signature of Reporting Person Date

_____ Robert Liptak, Manager of Clarus Ventures II,
 LLC 01/08/2010

__Signature of Reporting Person Date

_____ Robert Liptak, as attorney-in-fact for Nicholas
 Simon 01/08/2010

__Signature of Reporting Person Date

_____ Robert Liptak 01/08/2010

__Signature of Reporting Person Date

_____ Robert Liptak, as attorney-in-fact for Dennis
 Henner 01/08/2010

__Signature of Reporting Person Date

_____ Robert Liptak, as attorney-in-fact for Nicholas
 Galakatos 01/08/2010

__Signature of Reporting Person Date

_____ Robert Liptak, as attorney-in-fact for Jeffrey
 Leiden 01/08/2010

Edgar Filing: STEINMETZ MICHAEL - Form 4

_____ Wheeler	**Signature of Reporting Person Robert Liptak, as attorney-in-fact for Kurt	Date 01/08/2010
_____ Steinmetz	**Signature of Reporting Person Robert Liptak, as attorney-in-fact for Michael	Date 01/08/2010

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported on this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by Clarus Lifesciences II, L.P. (the "Fund") on November 1, 2009.

Securities held of record by the Fund. Clarus Ventures II GP, L.P. (the "GPLP"), as the sole general partner of the Fund, may be deemed to beneficially own certain of the shares held of record by the Fund. The GPLP disclaims beneficial ownership of all shares held of record by the Fund in which the GPLP does not have an actual pecuniary interest. Clarus Ventures II, LLC (the "GPLLC"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held of record by the Fund. Each of Messrs. Galakatos, Henner, Leiden, Liptak, Simon, Steinmetz and Wheeler, as individual Managing Directors of the GPLLC, may be deemed to beneficially own certain of the shares held of record by the Fund. Each of Messrs. Galakatos, Henner, Leiden, Liptak, Simon, Steinmetz and Wheeler disclaims beneficial ownership of all shares held of record by the Fund in which he does not have an actual pecuniary interest.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.